A Study to Evaluate the Effect of a Study Product on Quality of Life and Mood

KGK Science

Status and phase

Completed

Phase 2

Conditions

Quality of Life

Mood

Treatments

Dietary Supplement: Placebo

Dietary Supplement: Multivitamin

Dietary Supplement: Eurycomalongifoliawater extract (Physta®)

Study type

Interventional

Funder types

Industry

Identifiers

NCT02865863

BIOT2600

Details and patient eligibility

About

A phase II randomized, placebo controlled study evaluating the efficacy of Eurycomalongifoliawater extract (Physta®)+Multivitamin on quality of life and mood on 86 healthy adults over a 24 week supplementation period.

Enrollment

86 patients

Sex

All

Ages

25 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy subjects ≥ 25 and ≤ 65 years of age.
Body mass index (BMI) ≥ 18 and ≤30 kg/m2.
Subjects must be employed in a job/position that has some degree of responsibility such that they experience a mid-level of stress at work.
Subjects with a score of ≤ 18 in the Tension subscale and a score of ≤ 14 in the Fatigue subscale of the POMS Questionnaire.
Judged by the Investigator to be in general good health on the basis of medical history.
Females of child-bearing potential must agree to use appropriate birth control methods during the study.
Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator
Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator

Exclusion criteria

Subjects with any history of immune system disorder or auto-immune disorder including but not limited to the following:

*AIDS, HIV, Ankylosing Spondylitis, Chronic Fatigue Syndrome, CREST syndrome, Crohn's disease, Dermatomyositis, Fibromyalgia, Grave's disease, Hashimoto's Thyroiditis, Lupus, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, PolyarteritisNodosa, Primary Biliary Cirrhosis, Psoriasis, Reynaud's Syndrome, Rhematoid Arthritis, Sarcoidosis, Scleroderma, Sjogren's Syndrome, Temporal Arthritis, Ulcerative Colitis, and Vitiligo
Use of any immunosuppressive drugs in the last 12 months (including steroids or biologics)
Any significant GI condition that would severely interfere with the evaluation of the study product including but not limited to inflammatory bowel disease (Ulcerative Colitis or Chron's), history of frequent diarrhea, history of surgery for weight loss (including gastric bypass or lapband), history of perforation of the stomach or intestines, gastroparesis, clinically important lactose intolerance
Any active infection, or infection in the last month requiring antibiotics, antiviral medication, or hospitalization History or presence of cancer in the prior two years, except for non-melanoma skin cancer.
Subjects with a history of seizure
Recent history of (within 12 months) or strong potential for alcohol or substance abuse.
Participation in a clinical study with exposure to any non-registered drug product within 30 days prior.
Subject who are using herbal products containing androgenic/anxiolytic activity within 30 days (one month washout is allowed)
Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk. Including subjects who are Bed or wheelchair-bound
Untreated or unstable Hypothyroidism
Subjects with active eating disorder including anorexia nervosa, bulimia, and/or obsessive compulsive eating disorders
Central Neurological disorders including but not limited to Spinal cord injuries, multiple sclerosis, Parkinson's disease
Pregnant, lactating, planning to become pregnant or unwilling to use adequate contraception during the duration of the study.